- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05783882
Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma (FLAT)
Multicenter Open-label Study of the Efficacy, Pharmacokinetica and Safety of Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma
Multicentre, single-arm, open-label efficacy, pharmacokinetics, and safety study to demonstrate non-inferiority of prolgolimab 250 mg every 3 weeks versus historical data for prolgolimab 1 mg/kg every 2 weeks in patients with unresectable or metastatic melanoma, as well as collecting pharmacokinetics and safety data.
The study is conducted under the same conditions as the previously conducted study BCD-100-2/MIRACULUM. This means that this Study No. BCD-100-8/FLAT has identical parameters such as:
- selection criteria for subjects in the study, defining the population,
- research centers,
- procedures for evaluating effectiveness and safety,
- permitted prior and concomitant therapy of the underlying disease.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Arkhangel'sk, Russian Federation
- State Budgetary Institution of Healthcare of the Arkhangelsk Region "Arkhangelsk Regional Clinical Oncology Dispensary" (SBHI AR ARCOD)
-
Cheliabinsk, Russian Federation
- State Budgetary Institution of Healthcare "Clinical Oncology Dispensary of Chelyabinsk Region" (SBIH CODCR)
-
Moscow, Russian Federation
- N.N. Blokhin Russian Cancer Research Center
-
Moscow, Russian Federation
- State Budgetary Healthcare Institution "Moscow Clinical Scientific Center funded by Moscow Health Department" (SBHI MCSC MHD)
-
Saint-Petersburg, Russian Federation
- Federal State Budgetary Institution "N.N. Petrov Research Institute of Oncology" of the Ministry of Healthcare of the Russian Federation, Research Department of the Innovative Methods of Therapeutic Oncology and Rehabilitation
-
Saint-Petersburg, Russian Federation
- Federal State Budgetary Institution "N.N. Petrov Research Institute of Oncology" of the Ministry of Healthcare of the Russian Federation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent and the subject's ability to comply with the protocol requirements.
- Age ≥18 years at the time of informed consent.
- Histologically confirmed unresectable or metastatic melanoma (with available documented evidence of relevant examinations).
- Primarily detected advanced or metastatic melanoma, or the disease progression on or after previous systemic therapy.
- Measurable target tumor lesions (at least 1 lesion) according to RECIST 1.1 criteria, confirmed by an independent reviewer.
- ECOG score 0-1.
- Absence of severe organ and system disorders.
- Life expectancy of at least 12 weeks at screening.
- For patients of childbearing potential: willingness to use reliable methods of contraception throughout the study, from the time of informed consent and for up to 6 weeks after the last dose of the study drug.
- Available blocks for a histological examination and/or the patient's consent for collection of biopsy43 samples to obtain histological material to assess the PD-L1 status.
Exclusion Criteria:
- Patients with severe concomitant disorders, life-threatening acute complications of the primary disease (including massive pleural, pericardial, or peritoneal effusions requiring intervention, pulmonary lymphangitis) at the time of informed consent.
- CNS metastases that are progressing or associated with clinical symptoms (e.g., cerebral edema, spinal compression) or requiring the use of glucocorticosteroids and/or anticonvulsants;
- Ongoing concomitant diseases at the time of screening increasing the risk of severe adverse events during the study treatment.
- The need for glucocorticoids or any other drugs with immunosuppressive effects.
- Hematologic abnormalities.
- Renal impairment.
- Hepatic impairment.
- Increased LDH >2 ULN.
- Prior treatment with anti-CTLA4 and/or anti-PD-1/PD-L1/PDL-2 drugs.
- Prior targeted therapy.
- A history of malignancies, except for radically treated diseases in remission for over 5 years prior to starting the study.
- Conditions limiting the patient's ability to comply with the protocol requirements (dementia, neurologic or mental disorders, drug or alcohol addiction, etc).
- Simultaneous participation in other clinical studies55 or participation in other clinical studies within 30 days prior to starting the study treatmen.
- Acute infections or activation of chronic infectious diseases within 28 days prior to the beginning of the study treatment.
- Active hepatitis B, active hepatitis C, HIV-infection, syphilis.
- Impossibility to administer the study drug intravenously.
- Impossibility to perform imaging examinations requiring administration of intravenous contrast media.
- Hypersensitivity to any of the components of BCD-100.
- A history of hypersensitivity to monoclonal antibody products.
- Pregnancy or breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
|
250 mg Q3W
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate
Time Frame: 6 month
|
Overall response rate (partial response+complete response rates) according to RECIST 1.1
|
6 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate
Time Frame: 6 month
|
Overall response rate (partial response+complete response rates) according to irRECIST
|
6 month
|
Disease control rate
Time Frame: 6 month
|
Disease control rate (stabilization + partial response + complete response rates) according to RECIST 1.1
|
6 month
|
Disease control rate
Time Frame: 6 month
|
Disease control rate (stabilization + partial response + complete response rates) according to irRECIST
|
6 month
|
Time to response
Time Frame: 6 month
|
The time from the frirst administered dose to the response (partial or complete) according to RECIST 1.1
|
6 month
|
Time to response
Time Frame: 6 month
|
The time from the frirst administered dose to the response (partial or complete) according to irRECIST
|
6 month
|
Duration of Response
Time Frame: 6 month
|
Time from the response (partial or complete) repoerted date to the progression or death.
|
6 month
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BCD-100-8
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unresectable or Metastatic Melanoma
-
Pierre Fabre MedicamentCompletedMelanoma | BRAF V600E Unresectable or Metastatic Melanoma | BRAF V600E Metastatic NSCLCChina
-
Bristol-Myers SquibbActive, not recruitingUnresectable or Metastatic MelanomaUnited States, France, Poland, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, Germany, Ireland, Israel, Italy, Netherlands, New Zealand, Norway, Spain, Sweden, Switzerland, United Kingdom, Russian Federation
-
Ludwig Institute for Cancer ResearchCancer Research Institute, NY, USATerminatedNY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic MelanomaUnresectable or Metastatic MelanomaUnited States, Australia
-
Bristol-Myers SquibbCompletedUnresectable or Metastatic MelanomaUnited States, Germany, Italy, United Kingdom, Canada, Denmark, Netherlands, Spain, Belgium, France, Switzerland, Israel, Austria, Brazil
-
Zai Lab (Shanghai) Co., Ltd.TerminatedUnresectable, Recurrent or Metastatic Melanoma | Untreated Mucosal or Acral Lentiginous MelanomaChina
-
Case Comprehensive Cancer CenterCompletedMetastatic or Unresectable MelanomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable MelanomaUnited States
-
Incyte CorporationCompletedUnresectable or Metastatic Solid TumorsUnited States
-
Zhejiang UniversityNot yet recruitingUnresectable or Metastatic Advanced Solid Tumors
-
CytomX TherapeuticsTerminatedSolid Tumor | Unresectable or Metastatic MelanomaKorea, Republic of, United States, Netherlands, Spain, Australia
Clinical Trials on Prolgolimab
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
-
St. Petersburg State Pavlov Medical UniversityN.N. Petrov National Medical Research Center of OncologyRecruitingHodgkin LymphomaRussian Federation
-
BiocadRecruitingMelanoma (Skin) | Melanoma Stage IIIRussian Federation, Belarus